EA201390197A1 - Применение hmgb1 в качестве биологического маркера воспалительных состояний кишечника, неинвазивный способ его определения в образцах фекалий и набор для этого - Google Patents
Применение hmgb1 в качестве биологического маркера воспалительных состояний кишечника, неинвазивный способ его определения в образцах фекалий и набор для этогоInfo
- Publication number
- EA201390197A1 EA201390197A1 EA201390197A EA201390197A EA201390197A1 EA 201390197 A1 EA201390197 A1 EA 201390197A1 EA 201390197 A EA201390197 A EA 201390197A EA 201390197 A EA201390197 A EA 201390197A EA 201390197 A1 EA201390197 A1 EA 201390197A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- hmgb1
- kit
- fecal
- intestine
- definition
- Prior art date
Links
- 102000055207 HMGB1 Human genes 0.000 title abstract 3
- 108700010013 HMGB1 Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 title abstract 2
- 101150021904 HMGB1 gene Proteins 0.000 title abstract 2
- 230000002550 fecal effect Effects 0.000 title abstract 2
- 210000000936 intestine Anatomy 0.000 title abstract 2
- 239000000090 biomarker Substances 0.000 title 1
- 230000004968 inflammatory condition Effects 0.000 title 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 2
- 208000011231 Crohn disease Diseases 0.000 abstract 2
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 2
- 238000002965 ELISA Methods 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 239000000284 extract Substances 0.000 abstract 1
- 210000003608 fece Anatomy 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000008506 pathogenesis Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000001262 western blot Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM2010A000442A IT1406051B1 (it) | 2010-08-05 | 2010-08-05 | Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo. |
| PCT/IT2011/000276 WO2012017466A1 (en) | 2010-08-05 | 2011-08-01 | Use of hmgb1 as' a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201390197A1 true EA201390197A1 (ru) | 2013-06-28 |
Family
ID=43739596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201390197A EA201390197A1 (ru) | 2010-08-05 | 2011-08-01 | Применение hmgb1 в качестве биологического маркера воспалительных состояний кишечника, неинвазивный способ его определения в образцах фекалий и набор для этого |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20130137123A1 (enExample) |
| EP (1) | EP2601525A1 (enExample) |
| JP (1) | JP2013534313A (enExample) |
| CN (1) | CN103069276A (enExample) |
| AU (1) | AU2011287193B2 (enExample) |
| BR (1) | BR112013002145A2 (enExample) |
| CA (1) | CA2807107C (enExample) |
| CL (1) | CL2013000223A1 (enExample) |
| EA (1) | EA201390197A1 (enExample) |
| IL (1) | IL223845A (enExample) |
| IT (1) | IT1406051B1 (enExample) |
| MX (1) | MX2013001327A (enExample) |
| PE (1) | PE20131062A1 (enExample) |
| WO (1) | WO2012017466A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015067913A1 (en) | 2013-11-07 | 2015-05-14 | Diagnodus Limited | Biomarkers |
| PT2968443T (pt) | 2013-03-15 | 2021-12-28 | Protagonist Therapeutics Inc | Análogos de hepcidina e seus usos |
| SG10201810321PA (en) | 2014-05-16 | 2018-12-28 | Protagonist Therapeutics Inc | α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS |
| ES2977537T3 (es) | 2014-07-17 | 2024-08-26 | Protagonist Therapeutics Inc | Inhibidores peptídicos orales del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias intestinales |
| WO2017117411A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| WO2018089693A2 (en) * | 2016-11-09 | 2018-05-17 | Protagonist Therapeutics, Inc. | Methods for determining and monitoring gastrointestinal inflammation |
| DK3622082T3 (da) | 2017-05-12 | 2023-06-12 | Evonik Operations Gmbh | Fremgangsmåde til påvisning af c. perfringens-inducerede sygdomme i en fugleflok |
| IT201700083044A1 (it) | 2017-07-20 | 2019-01-20 | Laura Stronati | “uso della gelsolina come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali” |
| IT201700083055A1 (it) | 2017-07-20 | 2019-01-20 | Laura Stronati | “uso della proteina inibitore 2 della dissociazione di rho gdp come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali” |
| EP4501952A3 (en) | 2018-02-08 | 2025-04-16 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| CA3092472A1 (en) * | 2018-03-02 | 2019-09-06 | Evonik Operations Gmbh | In vitro method for detecting intestinal barrier failure in animals |
| CN109030817A (zh) * | 2018-07-04 | 2018-12-18 | 长沙都正医学检验有限责任公司 | Hmgb1检测试剂盒及其制备方法 |
| ES2938227T3 (es) | 2018-12-14 | 2023-04-05 | Evonik Operations Gmbh | Método in vitro de detección de disbiosis intestinal aviar |
| US11684653B2 (en) * | 2019-03-06 | 2023-06-27 | The Cleveland Clinic Foundation | Compositions and method for reducing virulence of microorganisms |
| CN115279782A (zh) | 2020-01-15 | 2022-11-01 | 詹森生物科技公司 | 白介素-23受体的肽抑制剂及其用于治疗炎性疾病的用途 |
| IL294680A (en) | 2020-01-15 | 2022-09-01 | Janssen Biotech Inc | Peptide inhibitors of the interleukin-23 receptor and their use for the treatment of inflammatory diseases |
| IL302996B2 (en) | 2020-11-20 | 2025-04-01 | Janssen Pharmaceutica Nv | Compositions of interleukin-23 receptor peptide inhibitors |
| AU2022311814A1 (en) | 2021-07-14 | 2024-02-29 | Janssen Biotech, Inc. | Lipidated peptide inhibitors of interleukin-23 receptor |
| CN116973572B (zh) * | 2023-06-02 | 2025-03-07 | 东南大学附属中大医院 | 基于血、粪便铁蛋白检测评估肠屏障损伤严重程度的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1577671A1 (en) * | 1996-07-17 | 2005-09-21 | Kaneka Corporation | Diagnostic drugs for autoimmune diseases |
| US6355623B2 (en) * | 1998-09-24 | 2002-03-12 | Hopital-Sainte-Justine | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
| US6303321B1 (en) * | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
| EP1601969A2 (en) * | 2003-03-08 | 2005-12-07 | Auvation Ltd | Markers for colorectal cancer |
| WO2007001422A2 (en) * | 2004-10-22 | 2007-01-04 | Medimmune, Inc. | High affinity antibodies against hmgb1 and methods of use thereof |
| WO2008075788A1 (ja) * | 2006-12-20 | 2008-06-26 | Shino-Test Corporation | ヒトｈｍｇｂ１と特異的に結合する鳥類由来の抗体、ヒトｈｍｇｂ１の免疫学的測定方法及びヒトｈｍｇｂ１の免疫学的測定試薬 |
| EP2185936A4 (en) * | 2007-08-02 | 2010-08-04 | Iss Immune System Stimulation | DIAGNOSIS, STADIFICATION AND SURVEILLANCE OF INFLAMMATORY ABDOMINAL DISEASE |
| US7833721B2 (en) * | 2008-03-14 | 2010-11-16 | Exagen Diagnostics, Inc. | Biomarkers for inflammatory bowel disease and irritable bowel syndrome |
-
2010
- 2010-08-05 IT ITRM2010A000442A patent/IT1406051B1/it active
-
2011
- 2011-08-01 JP JP2013522346A patent/JP2013534313A/ja active Pending
- 2011-08-01 CN CN2011800327624A patent/CN103069276A/zh active Pending
- 2011-08-01 AU AU2011287193A patent/AU2011287193B2/en not_active Ceased
- 2011-08-01 EA EA201390197A patent/EA201390197A1/ru unknown
- 2011-08-01 WO PCT/IT2011/000276 patent/WO2012017466A1/en not_active Ceased
- 2011-08-01 US US13/814,294 patent/US20130137123A1/en not_active Abandoned
- 2011-08-01 BR BR112013002145A patent/BR112013002145A2/pt not_active IP Right Cessation
- 2011-08-01 EP EP11754539.2A patent/EP2601525A1/en not_active Withdrawn
- 2011-08-01 PE PE2013000131A patent/PE20131062A1/es not_active Application Discontinuation
- 2011-08-01 MX MX2013001327A patent/MX2013001327A/es unknown
- 2011-08-01 CA CA2807107A patent/CA2807107C/en not_active Expired - Fee Related
-
2012
- 2012-12-24 IL IL223845A patent/IL223845A/en active IP Right Grant
-
2013
- 2013-01-23 CL CL2013000223A patent/CL2013000223A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20131062A1 (es) | 2013-10-16 |
| IT1406051B1 (it) | 2014-02-06 |
| IL223845A (en) | 2016-06-30 |
| US20130137123A1 (en) | 2013-05-30 |
| CA2807107A1 (en) | 2012-02-09 |
| WO2012017466A8 (en) | 2013-07-11 |
| CN103069276A (zh) | 2013-04-24 |
| BR112013002145A2 (pt) | 2016-05-24 |
| AU2011287193B2 (en) | 2015-08-13 |
| MX2013001327A (es) | 2013-03-08 |
| EP2601525A1 (en) | 2013-06-12 |
| CA2807107C (en) | 2017-01-03 |
| JP2013534313A (ja) | 2013-09-02 |
| ITRM20100442A1 (it) | 2012-02-06 |
| AU2011287193A1 (en) | 2013-06-13 |
| CL2013000223A1 (es) | 2014-03-28 |
| WO2012017466A1 (en) | 2012-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201390197A1 (ru) | Применение hmgb1 в качестве биологического маркера воспалительных состояний кишечника, неинвазивный способ его определения в образцах фекалий и набор для этого | |
| MA46219B1 (fr) | Composés de co-agonistes du glucagon et du glp-1 | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| Kofla-Dłubacz et al. | Metalloproteinase-3 and-9 as novel markers in the evaluation of ulcerative colitis activity in children | |
| DOP2011000274A (es) | Proteinas de union a il-17 | |
| BRPI1007321A2 (pt) | métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo. | |
| BR112012028920A2 (pt) | formulações de anticorpo de alta concentração | |
| EA201590523A1 (ru) | Il-18-связывающие молекулы | |
| EA201000424A1 (ru) | Антитела к il-23 | |
| AR084373A1 (es) | Composiciones y metodos para la eliminacion de biopeliculas | |
| WO2010060102A3 (en) | Prediction and prevention of preeclampsia | |
| ATE553778T1 (de) | Für humanes hepcidin spezifische antikörper | |
| EA201170357A1 (ru) | Инженерные антитела к il-13: композиции, способы и применение | |
| WO2011088385A3 (en) | Compositions and methods for detecting cancer | |
| BR112013000796A2 (pt) | Anticorpo isolado ou um fragmento de ligação ao antígeno, composição farmacêutica, métodos para inibir a montagem de ligantes difusíveis derivados de ß-amiloide, para inibir a fosforilação de proteína tau em ser202/thr205, para identificar um suposto agente terapêutico, para detectar ligantes difusíveis derivados de ß-amiloide e para diagnosticar uma doença associada aos ligantes difusíveis derivados de ß-amiloide, e, kit para detectar ligantes difusíveis derivados de ß-amiloide | |
| EA201792669A1 (ru) | Igfbp3 и его применение | |
| BRPI0712273A2 (pt) | Anticorpos isolados, polipeptídeos imunoglobulinas, anticorpo hepsina, molécula de ácido nucléico, célula hospedeira, linhagem celular, métodos para produzir o anticorpo, para diagnosticar a presença de hepsina, tratar uma doença, para monitorar a doença residual, para detectar o estado da doença, para diagnosticar uma disfunção, composição, arranjo ou chip de proteína e kit | |
| WO2011112670A3 (en) | Methods and compositions for chlamydial antigens for diagnosis and treatment of chlamydial infection and disease | |
| Benitez et al. | Brucella abortus induces collagen deposition and MMP-9 down-modulation in hepatic stellate cells via TGF-β1 production | |
| BR112012028010A2 (pt) | anticorpo isolado, célula, ácido nucleíco isolado, método de identificação de um primeiro anticorpo que se liga a um epítopo antigênico tat425 ligado or um anticorpo, métodos de inibir o crescimento de uma célula, de tratamento terapêutico de determinação da presença de uma proteína de tat425 e de diagnóstico da presença de um tumor em um mamífero | |
| EP2420515A4 (en) | DIAGNOSIS AND TREATMENT OF CANCER WITH ANTI-TMPRSS11E ANTIBODY | |
| FR2896588B1 (fr) | Methode de diagnostic in vitro de reponse immunitaire autoimmune par detection d'anticorps diriges contre l'antigene pentraxine 3. | |
| EP2243829A4 (en) | IMPROVED HUMANIZED ANTI-HUMAN 9-INTEGRIN ANTIBODY | |
| WO2014169011A3 (en) | Methods for treating immune diseases | |
| PL408905A1 (pl) | Nowy związek, sposób jego otrzymywania, roztwór farmaceutyczny zawierający nowy związek, sposób określania obecności choroby nowotworowej, zestaw do wykrywania nowotworów oraz zastosowanie hydrolizy nowego związku do wykrywania nowotworów |